Clinical Trial Success/Failure: As a clinical-stage biopharmaceutical company, the success or failure of its lead candidate, pemvidutide, in ongoing and upcoming clinical trials (especially the Phase 3 MASH trial) is a primary driver. Positive results lead to significant stock appreciation, while negative results can lead to sharp declines. The Breakthrough Therapy Designation is a positive factor for the stock.

Regulatory Approvals and Designations: FDA designations like Breakthrough Therapy (received for pemvidutide in MASH) are crucial as they can accelerate development and review, signaling potential market entry and future revenue streams.

Competition in the MASH/Obesity Market: The MASH and obesity markets are becoming increasingly competitive with several large pharmaceutical companies developing similar or competing drugs (e.g., GLP-1 agonists). The competitive landscape can influence Altimmune's potential market share and pricing power if its drug is approved.

Financing and Liquidity: As a company primarily in R&D, Altimmune's ability to raise capital through stock offerings or partnerships to fund extensive and costly clinical trials is critical for its long-term viability and development pipeline.